So, part of ,lur management of pcrwn,/patients with CERD must he rn aJdre,, qualit y o( lite issues, lll ascerta111 what 1:, thc snurce o( the anxiety.
The currcl:Hton hetween sym ptoms ,ind 'pH-mctry' is re,1sun:1hk (7) , hut nm su forendnsco1~Y (8, 9) . So why arc we Ml nften ga:ing at a video screen to grade rhe seventy of e~opha).!itis? Where i~ the el'idence for enJo~copic healing hcing r1ssnci;1ted with fewer recurrences o r fewer complications! Cenainly, recurrence ra1c~ fo r symptom~ a nd for L's11phag1t1s arc high so thcrc may well he a good reason to idcnt ify the presence of esophagi tis. Further in vestigation is approp riate for those persnm with (a) olarm symptoms (dysphagi,1, weighr los~. ancmia, hl eedi ng -worry: cancer or stricture); (b) persis1 ing symptoms after eight w 14 w.::eks of trcmment; nr (c) recurring ~ymptnms afte r recently ,uccessful therapy ( worry: erosive esophagi tis requiring murl.' pl1tenr acid inhibition and/or maintenance therapy). Dr John R Bennett ha~ prnvided a flow chart fnrcmpirical symptomatic Fii::urc l) (. \111adic111 ( ,ER i ) Con. 1,·n.1zi.1 deci. ,ion tree tn:,llmcnt ufl,ERD ( Figure 2 ) which is rc marbh ly similar to that ohtainl'd through o ur own indcpcmknt C anadian con, se1bw, ( I 0). I lz-rcn:pt,ir ,mtag(>nists "provide similar effeccivl' symp1 ,,m relief when g iven in equi valent dosagL' regimens" . Wh1k super ior symptom improvement c an he ,1chieved wnh a proto n pump inh1hitm rat her t h a n ,rn l lzrecepwr .rn tagon1st ( 11 ), thb st udy was not designed to con t rol vigorously for the assess me nt of follow-up c ndmcnp iL'S, nm 1s it gcnern ll y accepted that mnrc pmcnt ac id suppression he undertaken 111i 1 i.11ly in a ll persuns. Why no t ? Rcca11se. Because, why? Well, you dec ide -the adverse effect profile fo r shun term use of proron pump inhihitors a nd 112-reccplllr ,mt agonisb is equa ll y impressive. O n e could ,irgue that a n agent of superior efficacy a nd equiva lent cost a nd safct y profile he used for .111 e ndoscopy, hut t h a t was nnt the consemus. r'erhaps to identify hcuer those persons requ iri ng an cndl>scopy to identify erosive di sease, wh ic h is p(ten assncimed w ith recurrences and may require ,1ppmpriate discussion of I he USl' ,,I nrn1nte n:mce therapy. But patien ts with erosive esoph,1gius trcmcd wit h e ither an Hzreceptor anwgonb t rn a proton pump inhibi tor fm eight to 12 wceb and whu 1hcn col11L' llff t h erapy wi ll quickly reLur -some even suggest thm t hose c,, m111g off ac ute treat mc nt with a proton pump inhibitor mi ght recur more qu ic kl y, so 262 tha t an e n<loscopic s tudy would he done m rhat point a n yway. Some fu rthe r re fl ect ion is needed on thi s contcnti n us po int. An<l fo r the patiem who h as a rapid return of frequent symproms after coming off acute I h crapy (again with no a larm symptoms), what d o we d,l if endoscopy is nnrma l ! Probably more of t h e sam e, a not her course of an H z-receptor a ntagoni st (or a proton pump inhibito r) fo r e ight w 12 weeks. And then? Off trea tment agni n . What if t he sy mptoms recur ye t again ! Some suggest that it is u nn ecessary to perform a second proced ure. Y ct d o we know that the unde rl ying assumptio n is correct , th at once a normal endoscopy for CERD, al ways a n o rma l e ndoscopy? A Wayne's World 'NOT'! So why not simply use in termi ttent t herapy, criminate atte mpts to srnm p out H /)ylori ( 16) . W hil e sy mptmnatic recurrences of GERI) and Juo dcn a l ul cer d isease can huth be preve nted with continuo us t he ra py, it is on ly in the larter that fac tors h ave hecn identified whic h have an advcr c influen ce on recu rre nce rat es d uri ng con tinuo us l lzreceptor an tagon ist treatme nt: th ese incluJc smoking, stress, previous history of fre quent u lcer re larscs, a nd duration of disease fo r more than IO yea rs ( 17) . W hile thc rl' is clear evidence for a ll the H z-recepto r an1 agon ists bei n g superior to placebo for mai nten an cl' th erapy in d uoden al ulcer d isease (18) , and ev idence fo r lower duoden a l u lce r recu rrence rates with ranitidine th an wirh ci metidi nc ( 19, 20) , we do nut yet have comparat ive data for d iffe re n t H z-receptor an tagonbts m GERO. W e know chat th e risk of d uodena l u lcer d isease recurrence is kept low for a~ long as n ine years with ranit idine mai ntenance therapy (2 1 ). W e do no t yet know how l(111g to continue mai n ten ance th erapy in (,ERi); certainly grn,d o neyear remission rates may he ac hi eved using 150 or 300 mg ranitidine bid. O n e adva nt age nf us ing rani tidi nc 300 mg versus 150 mg fo r mai n te na nce thera py in duodenal u lcer tliscase is the lowe ri ng of rec urrence rates in sm nkcrs co th e level seen in no nsmokers. The re is the p re li m ina ry sugges-1ion that pro lo nged treatment with H z-receptor a n tagon ists reduces the risk fo r ulcer rec urrence once therapy h as hcen CAN J GASTROFNTl·ROI VOi 6 No 5 SFl'TFMBl:R/0<. "Tl1BER 1992 The maintenance dose for d uodennl ulcer d isease b ,mchal( the standard ulcer-h eali ng do~e. hut pat ients wi t h L :ERi 1 may need to he mainta ined on fu ll doses of Hz-receptor antagonists. Docs th is have adverse effects!Clinic.tll y important h ypcrgast rin em ia has not hcen descrihed in pat 1c1w, wit h duodena l ulce r Jiseasc a(t er fi ve yl'a rs oft real ment wi1 h rnni tid inc ( 2 5 ), ,ind we awai t wi th great in tl'rest t hL· ( >utcume of a major duodenal ulce r dise,isc ma i11tcnnnce ~111dy usi ng omcprnzolc.
Editorial
A new fie ld is under cult iv,ition -pharmacocconnmic considerat ions. There arc impmrnn t di rect as we ll as indi rect cosls, an d it is inefficient t,1 consider just th e uist of rncd ic,1t ion without abo establi shing the cost of investigat ions, ins! it ut ional care and losr prod ucti vity, let a lone I he va lue nf a person rema in ing p,ti n-frec. Ahnut one-th ird nfd irect costs re lates to drugs (26) , and d irect costs may he less than half of the tota l cost (27) . In a Fre nch mu l1icenrre st udy, maintemmce therapy fo r Juodc n:1 1 ulcer d isease with rani tidi nc 150 mg/day for 12 nHinths resulted in n 29% decreased tota l cost uf Juoden:tl u lcer di,ease compared with no mai nte n ance therapy (28) . Conti nuous t reatment with rani tid ine was t wice as cost-effective as interm ittent treatmen t. In the Un ited S tares, con tin uous versus in termittent th crary with rani ridinc reduces the cost of one successfull y tremed pa t ien t hy I 2'X,, or about$ I 00 (CanaJian) per year (29) . Another A me rica n study has shown that for at least 15 years con-
